Blood-Borne Diseases

Ervebo has been approved for the prevention of Ebola virus disease, caused by Zaire ebolavirus in individuals 18 years of age and older.

Ebola vaccines could be given as an emergency intervention to individuals exposed to the virus.

Observations about the body’s response to malaria infection can lead to new treatments for HIV and lupus, investigators believe.

An epidemiologist explores the changing epidemiology of a familiar disease.

The PALM trial evaluated the safety and efficacy of several experimental treatments for Ebola in the Democratic Republic of Congo.

TAF causes cholesterol levels to rise, but that includes levels of “good cholesterol” HDL. Researchers concluded that there is no significant difference in cardiovascular risk profiles between people taking TAF and those taking TDF.

Investigators now think that Ebola prevention methods should be a top priority moving forward.

Prequalification status indicates that the vaccine meets the WHO’s standard for efficacy, safety, and quality.

Since 2014 NYC Health + Hospitals has worked to maintain preparedness against diseases like Ebola.

Blood sample testing in African countries using rapid tests is a mixed message. Accuracy in HIV improved, but accuracy in hepatitis B and C testing did not.

Results from a study at a Cincinnati hospital point to the importance of testing at-risk infants for HCV as the opioid crisis impacts prevalence of the infection.

Leaders from the WHO and various impacted countries met to assess the risks of the Ebola outbreak in the Democratic Republic of the Congo and the future of the outbreak response.

Scientists from the National Institutes of Health are hopeful that diluting a dose of the VSV vaccine could be efficacious and stretch vaccine supplies even further.

Although the overall mortality rate for HCV has declined, clinicians will have to focus on individuated factors to address lingering barriers.

A patient was evaluated for Ebola in a Swedish hospital. Here's what we should take away from it.

One promising proposal to greatly increase access to DAA HCV therapy is to keep this treatment with appropriately trained PCPs, in contrast with referring patients to infectious disease, gastroenterology, or hepatology subspecialists.

The phase 1/2 trial of a prime-boost vaccine to prevent chronic HCV infection was completed in an at-risk population of in people who inject drugs.

The analysis of the survey responses found a statistically significant association in denial of the biomedical discourse and dissatisfaction or mistrust of the Ebola response as indicators of social resistance.

In part 2 of our Q&A with Fair, we talk about the challenges ahead in the fight against Ebola in the Democratic Republic of the Congo.

The FDA has approved treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to 8 weeks.

In part 1 of our Q&A with Fair, we talk about his background, education, and experience, and also how the outbreak response to the current Ebola outbreak in the DRC differs from traditional disaster response.

In this outbreak, 18% of Ebola cases have been tied to health care transmission. How can we prevent this from continuing?

The target action date for the V920 investigational Ebola vaccine is set for March 14, 2020.

Although drinking water-associated outbreaks are rarely reported in the United States, they were the most commonly reported etiology for outbreaks associated with untreated ground water from 1971-2008.

Investigators observed that, when compared with the general population of Guinea, survivors of Ebola had a 5-fold increased risk of mortality over a mean of 1 year of follow-up after discharge.